Drug intelligence / Profile preview

BCWP-D003

Development stage: Preclinical
Lead developer: BC World Pharm
Modality: Small Molecules
Administration: Intramuscular, Subcutaneous

Overview

BCWP-D003 is a long-acting injectable (LAI) formulation of an undisclosed small molecule antineoplastic agent being developed by BC World Pharm for the treatment of cancer. The drug is formulated as microspheres using BC World Pharm's proprietary Emulsifier-free SEP® Microsphere technology, which is designed to slowly release the active pharmaceutical ingredient over a one-month duration. BCWP-D003 is currently in the non-clinical (preclinical) stage of development in South Korea.

Beyond the preview

Go deeper on BCWP-D003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCWP-D003.

Explore the full profile